NCT07535840 2026-04-17
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Phase NA Not yet recruiting
Clinical Trials
23 trialsNCT07417800 2026-02-18
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Not yet recruiting
NCT06740370 2025-08-14
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting
NCT07077798 2025-07-22
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
Tongji Hospital
Phase NA Not yet recruiting
NCT06622031 2025-01-13
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Sun Yat-sen University
Phase NA Recruiting
NCT05215665 2024-12-11
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting
NCT06061276 2024-09-23
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Sun Yat-sen University
Phase NA Recruiting
NCT06070636 2024-08-09
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting
NCT04618367 2024-03-06
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Phase NA Completed
NCT02592356 2024-03-05
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
Phase NA Completed
NCT06277024 2024-02-26
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Fujian Medical University
Phase NA Recruiting
NCT05444478 2023-11-07
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting
NCT04642547 2023-08-01
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
RenJi Hospital
Phase NA Completed
NCT04967495 2023-05-18
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Second Affiliated Hospital of Guangzhou Medical University
Phase NA Unknown
NCT05592197 2023-02-16
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
Sun Yat-sen University
Phase NA Withdrawn
NCT05621499 2022-11-18
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT03838796 2022-08-02
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Fudan University
Phase NA Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT04443049 2021-10-05
To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
Institute of Liver and Biliary Sciences, India
Phase NA Unknown
NCT04531228 2021-09-22
Thalen
Sun Yat-sen University
Phase NA Unknown
NCT04961138 2021-07-14
Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Unknown
NCT04443322 2020-09-22
Dulect2020-1
RenJi Hospital
Phase NA Unknown
NCT04444193 2020-06-23
Dulect2020-2
Shanghai First Maternity and Infant Hospital
Phase NA Unknown